{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:14:32Z","timestamp":1791335672586,"version":"4.3.1"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2013,4,23]],"date-time":"2013-04-23T00:00:00Z","timestamp":1366675200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0061895","type":"journal-article","created":{"date-parts":[[2013,4,23]],"date-time":"2013-04-23T21:49:54Z","timestamp":1366753794000},"page":"e61895","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":126,"title":["Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity"],"prefix":"10.1371","volume":"8","author":[{"given":"W. Joost","family":"Lesterhuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Salmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esdy N.","family":"Rozali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Khong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Dick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Harken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce W.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,4,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd3500","article-title":"Cancer immunotherapy - revisited","volume":"10","author":"WJ Lesterhuis","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrc1613","article-title":"Immunotherapy and chemotherapy\u2013a practical partnership","volume":"5","author":"RA Lake","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"M Obeid","year":"2007","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI40269","article-title":"Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice","volume":"120","author":"R Ramakrishnan","year":"2010","journal-title":"J Clin Invest"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1172\/JCI43656","article-title":"Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice","volume":"121","author":"WJ Lesterhuis","year":"2011","journal-title":"J Clin Invest"},{"key":"ref6","first-page":"2353","article-title":"Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy","volume":"62","author":"AK Nowak","year":"2002","journal-title":"Cancer Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.4049\/jimmunol.170.10.4905","article-title":"Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells","volume":"170","author":"AK Nowak","year":"2003","journal-title":"J Immunol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","article-title":"Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses","volume":"102","author":"WM Liu","year":"2010","journal-title":"Br J Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1158\/0008-5472.CAN-10-2670","article-title":"Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice","volume":"71","author":"BL Mundy-Bosse","year":"2011","journal-title":"Cancer Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/ijc.25756","article-title":"Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells","volume":"129","author":"L Rettig","year":"2011","journal-title":"Int J Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00262-008-0653-8","article-title":"Ipilimumab: controversies in its development, utility and autoimmune adverse events","volume":"58","author":"J Weber","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"FS Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"ref13","unstructured":"Robert C, Thomas L, Bondarenko I, O\u2019Day S, M DJ, <etal>et al<\/etal>.. (2011) Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N Engl J Med."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1073\/pnas.1016791108","article-title":"Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance","volume":"108","author":"VA Pedicord","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref15","first-page":"4490","article-title":"Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors","volume":"63","author":"AK Nowak","year":"2003","journal-title":"Cancer Res"},{"key":"ref16","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, <etal>et al<\/etal>.. (2012) Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med."},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/onc.2010.500","article-title":"Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress","volume":"30","author":"I Martins","year":"2011","journal-title":"Oncogene"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1158\/0008-5472.CAN-11-1138","article-title":"The ICOS\/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy","volume":"71","author":"T Fu","year":"2011","journal-title":"Cancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"14987","DOI":"10.1073\/pnas.0806075105","article-title":"CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients","volume":"105","author":"CI Liakou","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, <etal>et al<\/etal>.. (2012) Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB\/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study. J Clin Oncol.","DOI":"10.1200\/JCO.2011.38.4032"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma","volume":"29","author":"EM Hersh","year":"2011","journal-title":"Invest New Drugs"},{"key":"ref22","first-page":"5301","article-title":"Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice","volume":"58","author":"MB Mokyr","year":"1998","journal-title":"Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Wu L, Yun Z, Tagawa T, Rey-McIntyre K, de Perrot M (2012) CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol Cancer Ther.","DOI":"10.1158\/1535-7163.MCT-11-1014"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00262-007-0291-6","article-title":"The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses","volume":"56","author":"M Chakraborty","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.vaccine.2003.10.048","article-title":"CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems","volume":"22","author":"PD Gregor","year":"2004","journal-title":"Vaccine"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0061895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T23:55:47Z","timestamp":1562975747000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0061895"}},"subtitle":[],"editor":[{"given":"Ramon Andrade","family":"de Mello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,4,23]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,4,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0061895","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,23]]}}}